Should I Buy PRCT? PRCT 2026 Analysis

Should You Buy Procept Biorobotics Corp (PRCT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

28.740

1 Day change

4.89%

52 Week Range

73.350

Analysis Updated At

2026/01/30

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

PRCT is not a good buy right now for an impatient buyer. The tape is still bearish (downtrend/weak momentum), there are no Intellectia buy signals, and fund-flow data shows hedge funds selling aggressively. While options positioning leans bullish (low put/call ratios) and fundamentals show strong revenue growth, the near-term setup looks more like a wait-for-confirmation situation (reclaiming ~$30.27 pivot and then ~$31.59 resistance) than a clean momentum entry today.

Intellectia Proprietary Trading Signals

AI Stock Picker: No signal on given stock today.
SwingMax: No signal on given stock today.

Technical Analysis

Trend and momentum remain bearish:

Moving averages: SMA_200 > SMA_20 > SMA_5 confirms a downtrend across long/intermediate/short timeframes.
MACD: Histogram -0.156 and negatively expanding, suggesting bearish momentum is strengthening rather than stabilizing.
RSI(6): 34.8 (near the oversold boundary but still labeled neutral here) indicates weakness; not yet a strong reversal signal.
Levels: Price $28.895 is sitting near S1 ~$28.964 (just below it), with next support S2 ~$28.155. Overhead resistance is Pivot ~$30.274 then R1 ~$31.585. Interpretation: The stock is hovering at support, but without a clear reversal trigger; a break below ~$28.15 would likely invite more downside, while strength back above ~$30.27 would be the first constructive sign.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options lean bullish-to-risk-on, but pricing implies elevated uncertainty:

Sentiment: Put/Call ratios are low (OI 0.66, Volume 0.45) = more call interest than puts.
Activity: Today’s option volume is 15.34x the 30-day average and OI is elevated (today vs avg OI 134.89%) → heightened positioning/attention.
Volatility: 30D IV 76.8% vs historical vol 47.4% (IV rich), IV percentile 72.8 → options are expensive, typically seen around uncertainty or catalysts. Takeaway: Traders are leaning bullish, but the market is charging a high premium for that exposure, consistent with a stock still in a shaky trend.

Technical Summary

Sell

Buy

Positive Catalysts

Fundamentals: 2025/Q3 revenue +42.76% YoY and gross margin 64.81% (+2.48% YoY) support a longer-term growth narrative.
Street still mostly constructive: multiple Buy/Overweight ratings remain and UBS called the selloff a buying opportunity.
Potential catalyst ahead: next earnings 2026-02-24 (after hours) could reset expectations if utilization trends re-accelerate.
Pattern-based projection provided suggests +3.64% next month (though near-term is weaker).

Neutral/Negative Catalysts

Price action: Clear bearish trend (bearish MA stack) and weakening MACD; no confirmed reversal yet.
Flow/positioning: Hedge funds are selling, with selling amount up 465.92% over the last quarter.
Business narrative risk: prior downgrade highlights utilization growth slowing and potential near-term disruption from changes to improve utilization.
No near-term news tailwind: no news in the recent week; catalyst calendar is mainly the next earnings date.
Options imply uncertainty: IV is elevated, often coinciding with larger moves and less favorable spot-entry timing.

Financial Performance

Latest quarter: 2025/Q3

Revenue: $83.33M, +42.76% YoY (strong top-line acceleration).
Net income: -$21.41M (loss improved +2.08% YoY, still unprofitable).
EPS: -0.38, -5.00% YoY (slightly worse YoY).
Gross margin: 64.81%, +2.48% YoY (positive mix/scale signal). Bottom line: Growth and margins are moving the right way, but profitability is not yet improving cleanly (EPS still deteriorated YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Recent trend: price targets have been cut across multiple firms, reflecting tempered near-term expectations, but ratings remain largely constructive.

Bullish/positive: UBS initiated Buy $62 (12/12). Truist kept Buy (PT cut to $47). Morgan Stanley kept Overweight (PT cut to $51). TD Cowen, Piper Sandler, Wells Fargo kept Buy/Overweight with PTs around ~$50-51 after cuts.
Bearish/tempering: BofA downgraded to Neutral with PT $38 (from $55), citing slowing utilization and potential disruption. Wall Street pros vs cons summary:
Pros: large market opportunity, utilization growth potential in 2026/27, margin expansion narrative.
Cons: near-term utilization/system growth slowdown and execution risk; targets trending lower even among bulls.

10 Analyst Rating

Wall Street analysts forecast PRCT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRCT is 51.75 USD with a low forecast of 38 USD and a high forecast of 65 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

8 Buy

2 Hold

0 Sell

Strong Buy

Current: 27.400

Low

Averages

51.75

High

Current: 27.400

Low

Averages

51.75

High

Truist

Richard Newitter

Buy

downgrade

$50 -> $47

AI Analysis

2025-12-18

Reason

Truist

Richard Newitter

Price Target

$50 -> $47

AI Analysis

2025-12-18

downgrade

Buy

Reason

Truist analyst Richard Newitter lowered the firm's price target on Procept BioRobotics to $47 from $50 and keeps a Buy rating on the shares as part of a broader research note previewing 2026 for MedTech. The firm is more positive on the industry heading into next year given a more attractive relative sector valuation, though it also sees the possibility of it being a "source" vs. a destination of new healthcare investment flows, the analyst tells investors in a research note. Truist adds it prefers names with 2026 catalysts fueling durable revenue acceleration or out-of-favor near-term narratives.

UBS

Danielle Antalffy

Buy

initiated

$62

2025-12-12

Reason

UBS

Danielle Antalffy

Price Target

$62

2025-12-12

initiated

Buy

Reason

UBS analyst Danielle Antalffy initiated coverage of Procept BioRobotics with a Buy rating and $62 price target. The firm's key onion leader checks provide conviction in the company's utilization growth in 2026 and 2027. It views the recent selloff in the shares as a buying opportunity. Procept's focus on driving utilization on its existing installed base, underpenetrated system placement market, and mix-driven margin expansion are underappreciated by the market, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PRCT

Unlock Now

PRCT Should I Buy

PRCT Should I Buy

Should You Buy Procept Biorobotics Corp (PRCT) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch